NFKB1 and hepatocellular carcinoma: A study proposed that the LXRs are potent prognostic biomarker in HCC patients, which inhibits the expression levels of MMP-2 and MMP-9 via NFκB pathway upon activated by agonist GW3965 (Long et al., 2018).